Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Rachel Knight

Clinical Nurse Specialist, Gerontology Cortland, OH Nurse Practitioner

NPI 1194273912 CMS profile 10901881

2600 Elm Rd Ne, Cortland, OH 44410

Open in the dashboard

General payments

$1,655

81 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rachel Knight of Cortland, OH is reported in the CMS Open Payments database as having received $1,655 across 81 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Clinical Nurse Specialist, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $683 36
2024 General $685 35
2023 General $201 9
2021 General $86 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rachel Knight
  • Clinical Nurse Specialist, Gerontology median
  • Middle half of Clinical Nurse Specialist, Gerontology
  • National median

In program year 2025, general payments to Rachel Knight were reported at $683. Among 115 Clinical Nurse Specialist, Gerontology profiles paid that year, the median was $161 and the middle half received between $80 and $556.

Show as a table
Year Rachel Knight Clinical Nurse Specialist, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $86 $146 $38–$369 $132
2022 $0 $127 $48–$336 $149
2023 $201 $174 $43–$492 $160
2024 $685 $209 $72–$472 $164
2025 $683 $161 $80–$556 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $303 14 payments
  2. AstraZeneca Pharmaceuticals LP $196 8 payments
  3. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $167 9 payments
  4. Amgen Inc. $155 9 payments
  5. BridgeBio Pharma, Inc. $103 4 payments
  6. Merck Sharp & Dohme Corporation $77 4 payments
  7. Pfizer Inc. $77 4 payments
  8. E.R. Squibb & Sons, L.L.C. $71 5 payments
  9. Kiniksa Pharmaceuticals International, plc $58 4 payments
  10. Novo Nordisk Inc $57 3 payments
  11. Other $391 17 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,590 80 payments
  2. Education $65 1 payment
Products named General payments · program years 2021–2025
  1. LifeVest $167 9 payments
  2. LEQVIO $164 8 payments
  3. ENTRESTO $158 7 payments
  4. Attruby $103 4 payments
  5. FARXIGA $86 5 payments
  6. Repatha Cardiology $81 5 payments
  7. VERQUVO $77 4 payments
  8. REPATHA Cardiovascular $74 4 payments
  9. ATACAND $65 1 payment
  10. ELIQUIS $59 3 payments
  11. Other $721 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

4,192

Median for Nurse Practitioner: 389

Drug cost

$950,046

Median for Nurse Practitioner: $21,885

Branded share of claims

24.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 434 $531,153
Entresto Sacubitril/Valsartan Brand 87 $134,483
Xarelto Rivaroxaban Brand 89 $107,379
Repatha Sureclick Evolocumab Brand 50 $49,209
Jardiance Empagliflozin Brand 31 $43,007
Brilinta Ticagrelor Brand 34 $29,286
Farxiga Dapagliflozin Propanediol Brand 20 $17,884
Metoprolol Succinate Generic 345 $4,915
Rosuvastatin Calcium Generic 284 $3,740
Atorvastatin Calcium Generic 389 $3,477

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$17,498

Medicare's payments for the services billed

Medicare patients

210

Average age 76

Services billed

325

107 women, 103 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 73%
Heart failure 61%
Atrial fibrillation 52%
Arthritis 50%
Chronic kidney disease 48%
Diabetes 46%
COPD 35%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $106
$106 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $105
$105 87 —
ATACAND
  • AstraZeneca Pharmaceuticals LP $65
$65 — —
Repatha
  • Amgen Inc. $60
$60 50 —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $58
$58 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

81 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Gerontology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record